High expression levels of IFITM3 (interferon‐induced transmembrane protein 3),9NAT10 (N‐acetyltransferase 10),10TET3,11PPM1D (protein phosphatase Mg2+/Mn2+‐dependent 1D)12 and Wnt1113 have been identified as poor prognostic biomarkers in patients with AML, potentially guiding AML management. This evidence concerns the gene IFITM3 and acute myeloid leukemia.